Stocks Health care BNTX
NASDAQ · Health careBioNTech SE (BNTX)
BioNTech SE reported revenue of €2.9B in fiscal 2025, up 4.3% from a year earlier. It posted a net loss of €1.1B. Operating cash flow minus capital spending left €280.9M of free cash flow in fiscal 2025. At December 31, 2025 it held €7.7B in cash. Its latest periodic report to the SEC is the annual report (foreign issuer, amended) (20-F/A) filed on July 30, 2026.
What BioNTech SE does
BioNTech SE is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BNTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | €2.9B | -€1.1B | -€4.70 | €280.9M |
| 2024 | €2.8B | -€665.3M | -€2.77 | -€78.8M |
| 2023 | €3.8B | €930.3M | €3.83 | €5.1B |
| 2022 | €17.3B | €9.4B | €37.77 | €13.2B |
| 2021 | €19B | €10.3B | €39.63 | €762.2M |
| 2020 | €482.3M | €15.2M | €0.06 | -€79.5M |
Latest SEC filings
What BioNTech SE has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026
- September 14, 2026
- August 28, 2026
- August 27, 2026
- August 20, 2026
- August 4, 2026
- August 4, 2026
- August 3, 2026
- July 30, 2026Annual report (foreign issuer, amended) 20-F/A · period to December 31, 2025
- July 29, 2026
Questions about BNTX
What does BioNTech SE do?
BioNTech SE is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BNTX.
Is BioNTech SE profitable?
No. In fiscal 2025 it reported a net loss of €1.1B on revenue of €2.9B.
How much revenue does BioNTech SE make?
In fiscal 2025 BioNTech SE reported revenue of €2.9B. That is 4.3% more than a year earlier.
When did BioNTech SE last report?
Its most recent periodic report is the annual report (foreign issuer, amended) (20-F/A) filed on July 30, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the insider trade from September 24, 2026.
Similar companies
Follow BNTX
Get an email when BioNTech SE files with the SEC: results, executive changes, material agreements and annual reports.
Follow BNTX: get an email when it filesWhere the numbers come from
Financial figures are the values BioNTech SE tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.